K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · PFIZER
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | PFE | PFIZER | FEDERAL HEALTH POLICY STRATEGIES | $60K | Drug pricing and prescription digital therapeutics |
| 2026-04-20 | PFE | PFIZER | WILLIAMS AND JENSEN, PLLC | $60K | General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21. Tax issues affecting the pharmaceutical industry including international tax; implementation of PL 119-21. Vaccine excise tax issues and VICP. Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21. Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962. Policies impacting post pandemic public health emerge |
| 2026-04-20 | PFE | PFIZER | RESOLUTION PUBLIC AFFAIRS, LLC | $60K | Issues related to drug development and pricing, generally vaccine safety and access, generally the 340B program, Issues related to pharmacy benefit managers, generally. H.R. 5509, the Safe Step Act Direct-to-Patient Prescription Drug Purchase Platforms Most Favored Nation drug pricing 340B HHS Pilot Program Model |
| 2026-01-20 | PFE | PFIZER | FEDERAL HEALTH POLICY STRATEGIES | $60K | Drug pricing and prescription digital therapeutics |
| 2026-01-20 | PFE | PFIZER | RESOLUTION PUBLIC AFFAIRS, LLC | $60K | Issues related to drug development and pricing, generally vaccine safety and access, generally the 340B program, Issues related to pharmacy benefit managers, generally. |
| 2026-01-20 | PFE | PFIZER | WILLIAMS AND JENSEN, PLLC | $60K | General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21. Tax issues affecting the pharmaceutical industry including international tax; implementation of PL 119-21. Vaccine excise tax issues and VICP. Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21. Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962. Policies impacting post pandemic public health emerge |
| 2025-10-20 | PFE | PFIZER | FEDERAL HEALTH POLICY STRATEGIES | $60K | Implementation of the drug pricing provisions in the Inflation Reduction Act Drug pricing and prescription digital therapeutics |
| 2025-10-20 | PFE | PFIZER | WILLIAMS AND JENSEN, PLLC | $60K | Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21. Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access, access to migraine screening. Support for tick-borne disease research and womens health. Issues related to pharmaceutical manufacturing and development. General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. P |
| 2025-10-20 | PFE | PFIZER | RESOLUTION PUBLIC AFFAIRS, LLC | $40K | Issues related to drug development and pricing, generally vaccine safety and access, generally the 340B program, Issues related to pharmacy benefit managers, generally. |
| 2025-10-16 | PFE | PFIZER | RESOLUTION PUBLIC AFFAIRS, LLC | $0 | Issues impacting Rx development and sales, generally |
| 2025-07-21 | PFE | PFIZER | FEDERAL HEALTH POLICY STRATEGIES | $60K | Implementation of the drug pricing provisions in the Inflation Reduction Act Drug pricing and prescription digital therapeutics |
| 2025-07-21 | PFE | PFIZER | WILLIAMS AND JENSEN, PLLC | $60K | General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals. H.R. 1; issues related to biopharmaceutical drug pricing, particularly related to MFN. Tax issues affecting the pharmaceutical industry including international tax; including tax issues under consideration for reconciliation legislation and H.R. 1, One Big Beautiful Bill Act". Vaccine excise tax issues and VICP. Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actio |
| 2025-04-21 | PFE | PFIZER | WILLIAMS AND JENSEN, PLLC | $60K | General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; drug importation; and drug shortages. Drug pricing proposals. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). PASTEUR Act. Pharmacy benefit manager reform proposals. Tax issues affecting the pharmaceutical industry including international tax. Vaccine excise tax issues and VICP. Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. Issues related to pharmaceutical manufacturing and development, trade and tariffs. Legislative proposals related to WTO TRIPS Waiver. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunizatio |
| 2025-04-21 | PFE | PFIZER | SHOOK, HARDY & BACON, LLP | $0 | |
| 2025-04-18 | PFE | PFIZER | FEDERAL HEALTH POLICY STRATEGIES | $60K | Implementation of the drug pricing provisions in the Inflation Reduction Act Drug pricing and prescription digital therapeutics |
| 2025-01-22 | PFE | PFIZER | WILLIAMS AND JENSEN, PLLC | $60K | General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; drug importation; and drug shortages. Drug pricing proposals. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). PASTEUR Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158). Tax issues affecting the pharmaceutical industry including international tax. Vaccine excise tax issues and VICP. Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. |
| 2025-01-21 | PFE | PFIZER | FEDERAL HEALTH POLICY STRATEGIES | $60K | Implementation of the drug pricing provisions in the Inflation Reduction Act Access to Prescription Digital Therapeutics Act (H.R. 1458) H.R. 8816, the American Medical Innovation and Investment Act |
| 2025-01-21 | PFE | PFIZER | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $30K | Support increased funding for the CDC National Immunization Program (Sec 317 program). Support increased funding for the CDC National Immunization Program (Sec 317 program) |
| 2025-01-21 | PFE | PFIZER | SHOOK, HARDY & BACON, LLP | $0 |